Skip to main content

Perlegen Rounds Up $30 Million

NEW YORK, Jan. 27-Perlegen Sciences said today that it had closed a private placement of Series C Preferred Stock worth $30 million.

 

The round was led by Maverick Capital and included both new and repeat investors, among them Eli Lilly, Vulcan Ventures, Unilever Technology Ventures and SB Life Science Ventures.

 

Perlegen is an Affymetrix spinoff. It is based in Mountain View, Calif.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.